Elevated [18F]FDOPA utilization in the periaqueductal gray and medial nucleus accumbens of patients with early Parkinson's disease

被引:25
|
作者
Kumakura, Yoshitaka [1 ,2 ]
Danielsen, Erik H. [1 ,3 ]
Gjedde, Albert [1 ,3 ]
Vernaleken, Ingo [4 ]
Buchholz, Hans-Georg [5 ]
Heinz, Andreas [6 ]
Gruender, Gerhard [4 ]
Bartenstein, Peter [7 ]
Cumming, Paul [7 ]
机构
[1] Aarhus Univ, Ctr Functionally Integrat Neurosci, DK-8000 Aarhus C, Denmark
[2] Univ Tokyo, Grad Sch Med, Dept Nucl Med, Tokyo 1138654, Japan
[3] Aarhus Univ Hosp, Dept Neurol, Aarhus, Denmark
[4] Rhein Westfal TH Aachen, Dept Psychiat & Psychotherapy, Aachen, Germany
[5] Johannes Gutenberg Univ Mainz, Dept Nucl Med, D-6500 Mainz, Germany
[6] Charite Hosp, Dept Psychiat, Berlin, Germany
[7] Univ Munich, Dept Nucl Med, Munich, Germany
基金
日本科学技术振兴机构;
关键词
Parkinson's disease; FDOPA; Periaqueductal gray; Nucleus accumbens; POSITRON-EMISSION-TOMOGRAPHY; DORSAL RAPHE NUCLEUS; DOPA DECARBOXYLASE ACTIVITY; BRAIN TRANSFER CONSTANTS; TIME UPTAKE DATA; SEROTONERGIC NEURONS; GRAPHICAL EVALUATION; STORAGE CAPACITY; F-18-DOPA PET; FDOPA UPTAKE;
D O I
10.1016/j.neuroimage.2009.11.035
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
PET studies with the DOPA decarboxylase substrate 6-[F-18]fluoro-L-DOPA (FDOPA) reveal the storage of [F-18]-fluorodopamine within synaptic vesicles, mainly of dopamine fibres. As such, FDOPA PET is a sensitive indicator of the integrity of the nigrostriatal dopamine innervation. Nonetheless, there have been several reports of focal elevations of FDOPA utilization in brain of patients with Parkinson's disease (PD), all based on reference tissue methods. To investigate this phenomenon further, we used voxel-wise steady-state kinetic analysis to search for regions of elevated FDOPA utilization (K: ml g(-1) min(-1)) and steady-state trapping (V-d; ml g(-1)) in a group of well-characterized patients with early, asymmetric PD, who were contrasted with an age-matched control group. Subtraction of the population mean parametric maps revealed foci of increased FDOPA utilization K (+25%) in the bilateral medial nucleus accumbens, whereas the expected declines in the trapping of FDOPA were seen in the caudate and putamen. This observation suggests hyperfunction of catecholamine fibres innervating specifically the limbic striatum, which could guide the design of future prospective FDOPA-PET studies of the impulse control disorders occurring in some PD patients under treatment with dopamine agonists. A focus of increased FDOPA influx and also Vd was detected in the periaqueductal grey, consistent with some earlier reports based on reference tissue analysis. Increased FDOPA trapping in the periaqueductal grey of PD patients seems consistent with recent reports of increased activity of serotonin neurons in a rat model of parkinsonism. (C) 2009 Elsevier Inc. All rights reserved.
引用
收藏
页码:2933 / 2939
页数:7
相关论文
共 50 条
  • [31] [18F]Florbetapir PET Imaging in Cognitively Normal Parkinson's Disease
    Chen, Yin
    Nasrallah, Ilya
    Gross, Rachel Goldmann
    Akhtar, Rizwan
    Hurtig, Howard
    Chen-Plotkin, Alice
    Chahine, Lama
    Trojanowski, John
    Weintraub, Daniel
    Dubroff, Jacob
    JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (03)
  • [32] Comparative analysis of striatal [18F]FDOPA uptake in a partial lesion model of Parkinson's disease in rats: Ratio method versus graphical model
    Avendano-Estrada, Arturo
    Verdugo-Diaz, Leticia
    Avila-Rodriguez, Miguel A.
    SYNAPSE, 2022, 76 (5-6)
  • [33] Levodopa effect on [18F]fluorodopa influx to brain:: normal volunteers and patients with Parkinson's disease
    Kumakura, Y
    Danielsen, EH
    Reilhac, A
    Gjedde, A
    Cumming, P
    ACTA NEUROLOGICA SCANDINAVICA, 2004, 110 (03): : 188 - 195
  • [34] Increased frontal [18F]fluorodopa uptake in early Parkinson's Disease:: sex differences in the prefrontal cortex
    Kaasinen, V
    Nurmi, E
    Brück, A
    Bergman, J
    Solin, O
    Rinne, JO
    BRAIN, 2001, 124 : 1125 - 1130
  • [35] Striatal dopaminergic depletion in initial unilateral Parkinson's Disease: a 18F-FDOPA PET study
    Arbizu, J
    Rodriguez-Fraile, M
    Rodriguez-Oroz, MC
    Marti-Climent, JM
    Obeso, JA
    Richter, JA
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2004, 31 : S370 - S370
  • [36] Crossover study of 99mTc-TRODAT-1 SPECT and 18F-FDOPA PET in Parkinson's disease patients
    Huang, WS
    Chiang, YS
    Lin, JC
    Chou, YH
    Cheng, CY
    Liu, RS
    JOURNAL OF NUCLEAR MEDICINE, 2003, 44 (07) : 999 - 1005
  • [37] A within-subject comparison of 6-[18F]Fluoro-m-Tyrosine (FMT) and 6-[18F]Fluoro-l-DOPA (FDOPA) in Parkinson disease (PD)
    Gallagher, Catherine L.
    Holden, James
    Christian, Brad
    Harding, Sandra
    Nickles, Robert J.
    Johnson, Sterling
    NEUROIMAGE, 2010, 52 : S75 - S75
  • [38] 18F fluorodopa uptake change in Parkinson's disease with and without dementia.
    Kato, T
    Nagano-Saito, A
    Arahata, Y
    Abe, Y
    Nakamura, A
    Ogawa, M
    Suzuki, M
    Kawasumi, Y
    Hatano, K
    Iwai, K
    Horibe, K
    Yamada, T
    Washimi, Y
    Kachi, T
    Ito, K
    JOURNAL OF NUCLEAR MEDICINE, 2001, 42 (05) : 226P - 226P
  • [39] PET imaging of mGluR5 with [18F]FPEB in Parkinson's disease
    Kang, Y.
    He, B.
    Verma, A.
    Henchcliffe, C.
    Kothari, P. J.
    Schlyer, D.
    Schmidt, K.
    Chiao, P. C.
    Vallabhajosula, S.
    Mozley, P. D.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S194 - S194
  • [40] No Dopamine Agonist Modulation of Brain [18F]FEOBV Binding in Parkinson's Disease
    Albin, Roger L.
    Kanel, Prabesh
    van Laar, Teus
    van der Zee, Sygrid
    Roytman, Stiven
    Koeppe, Robert A.
    Scott, Peter J. H.
    Bohnen, Nicolaas, I
    MOLECULAR PHARMACEUTICS, 2022, 19 (04) : 1176 - 1182